Back to Search
CELESTIA HIGANO, MD
MD
Hematology & Oncology Physician
NPI: 1972689727Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
00019850(WA)
Research & Publications (20)
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
PMID 19536890·Cancer·2009
3-trial
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.
PMID 18646045·Cancer·2008
3-trial
Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
PMID 18185511·Nat Clin Pract Urol·2008
6-review
Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
PMID 18404692·Cancer·2008
8-other
Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone.
PMID 18501082·Clin Genitourin Cancer·2008
8-other
Androgen deprivation therapy: monitoring and managing the complications.
PMID 16861122·Hematol Oncol Clin North Am·2006
6-review
Current status of treatment for patients with metastatic prostate cancer.
PMID 16018832·Can J Urol·2005
6-review
Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
PMID 15123412·Urol Clin North Am·2004
4-observational
Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.
PMID 15596194·Urology·2004
8-other
Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer.
PMID 14977818·Clin Cancer Res·2004
3-trial
Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.
PMID 12667885·Urology·2003
6-review
Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells.
PMID 19507029·Dig Dis Sci·2010
8-other
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).
PMID 19608618·Ann Oncol·2010
3-trial
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
PMID 19167733·J Urol·2009
2-rct
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
PMID 19213669·Clin Genitourin Cancer·2009
8-other
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
PMID 19359544·Science·2009
3-trial
Prostate cancer-associated gene expression alterations determined from needle biopsies.
PMID 19366833·Clin Cancer Res·2009
4-observational
Does chemotherapy have a role before hormone-resistant disease develops?
PMID 19371481·Curr Urol Rep·2009
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3515 E SPRING ST
SEATTLE, WA 98122 - Phone
- (206) 972-7952
Quick Facts
- NPI
- 1972689727
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile